Journal article
In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.
Abstract
SOURCE CITATION: Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.
Authors
Santos-Gallego CG; Van Spall HGC
Journal
Annals of Internal Medicine, Vol. 174, No. 6,
Publisher
American College of Physicians
Publication Date
6 2021
DOI
10.7326/acpj202106150-068
ISSN
1056-8751